Regentis Biomaterials Ltd. (RGNT)
NYSEAMERICAN: RGNT · Real-Time Price · USD
3.255
-0.105 (-3.12%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Regentis Biomaterials Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -13.65 | 4.8 | -4.13 | -1.45 | -5.14 | |
| Other Amortization | 0.25 | 0.16 | 0.17 | - | - | |
| Stock-Based Compensation | 7.04 | - | - | - | - | |
| Other Operating Activities | 4.86 | -4 | 2.03 | 0.07 | 4.42 | |
| Change in Accounts Payable | 0.01 | -0.1 | 0.15 | -0.1 | -0.03 | |
| Change in Other Net Operating Assets | 0.12 | -1.5 | 0.56 | -0.02 | 0.88 | |
| Operating Cash Flow | -1.38 | -0.64 | -1.22 | -1.5 | 0.13 | |
| Short-Term Debt Issued | 0.3 | 0.4 | 0.33 | - | - | |
| Long-Term Debt Issued | - | 0.45 | - | - | 1.24 | |
| Total Debt Issued | 0.3 | 0.85 | 0.33 | - | 1.24 | |
| Short-Term Debt Repaid | - | -0.33 | - | - | - | |
| Total Debt Repaid | - | -0.33 | - | - | - | |
| Net Debt Issued (Repaid) | 0.3 | 0.53 | 0.33 | - | 1.24 | |
| Issuance of Common Stock | 8.22 | - | - | - | - | |
| Financing Cash Flow | 8.52 | 0.53 | 0.33 | - | 1.24 | |
| Net Cash Flow | 7.15 | -0.12 | -0.9 | -1.5 | 1.37 | |
| Levered Free Cash Flow | 3.03 | -0.89 | -0.25 | -1.1 | 0.4 | |
| Unlevered Free Cash Flow | 2.83 | -1.04 | -0.42 | -1.1 | 0.4 | |
| Change in Working Capital | 0.13 | -1.6 | 0.71 | -0.12 | 0.85 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.